On Aug. 5, 2020, Pfizer and Shanghai Fosun Pharmaceutica announced that the first 72 participants had been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration. The trial was part of BioNTechﾒs global development program aimed at supporting a global supply upon regulatory approval.